PROCR Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-9506R |
| Product Name | PROCR Polyclonal Antibody |
| Applications |
WB
IHC-P
IF(IHC-P)
|
| Reactivity | Mouse |
| Predicted Reactivity | Human, Rat |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human EPCR/CD201 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 10544 |
| Subcellular location | Extracellular |
| Synonyms | Activated protein C receptor; APC receptor; APCR; CCCA; CCD41; CD201 antigen; centrocyclin; Endothelial cell protein C receptor; MGC23024; PROCR; EPCR_HUMAN; CD201. |
| Background | EPCR is a receptor for activated protein C, a serine protease activated by and involved in the blood coagulation pathway. It is an N glycosylated type I membrane protein that enhances the activation of protein C. Mutations in this gene have been associated with venous thromboembolism and myocardial infarction, as well as with late fetal loss during pregnancy. It is expressed strongly in the endothelial cells of arteries and veins in heart and lung. It is overexpressed in several human non-Pgp multidrug resistant (MDR) tumor cell lines. Whether and how anti-coagulant and anti-inflammatory functions of EPCR facilitate oncogenesis and/or drug resistance is unclear. |
| Application Dilution | |
| WB | 1:300-5000 |
| IHC-P | 1:200-400 |
| IF(IHC-P) | 1:50-200 |